Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (19021)	4/14/1998 9:32:00 AM
From: Henry Niman	Respond to of 32384

Mudcat, I really don't think that you understand what is and is not to be expected in the popular press articles. The NY Times article was in the "Science" section and was on Tamoxifen. As noted, even when the upcoming followup prevention trial pitting Tamoxifen against Evista was mentioned, there was no mention of LLY, Evista, or Raloxifene. The articles are NOT intended to present a list of compounds under development or companies developing them. NO COMPANY was mentioned in the entire article, even though it was quite lengthy. NO COMPOUND was mentioned although many SERMs (Evista, Droloxifene, Idoxifene, CP-366,156, TSE424) being developed by several companies (LLY, PFE, AHP, SBH), and some other compounds (Targretin, Panretin) have chemopreventive properties and they synergize with Tamoxifen. To expect Targretin, Panretin, or Ligand to be mentioned in such an article is extremely chavinistic, and not reality based.